You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

Introduction

More than one-third of adults in the United States are obese. It should come as no surprise that these individuals are at increased risk for cardiovascular disease, diabetes, certain cancers, and other significant comorbidities. If current trends continue, nearly 60% of US adults will be overweight or obese by 2030. New guidelines and pharmacotherapy are available to assist the medical community in its efforts to manage this disease. Experts in obesity share their insights on the latest approaches and treatment options for overweight and obese patients.

Activities

Steering Committee

Steering Committee Chair
  • Ken Fujioka, MDKen Fujioka, MD
    Director, Nutrition and Metabolic Research Center, Scripps Clinic, La Jolla, California
Steering Committee Members
  • Timothy Church, MD, MPH, PhDTimothy Church, MD, MPH, PhD
    Professor, Pennington Biomedical Research Center, Baton Rouge, Louisiana
  • Timothy Garvey, MDTimothy Garvey, MD
    Butterworth Professor and Chair, Department of Nutrition Sciences, University of Alabama at Birmingham; Director, UAB Diabetes Research Center; Investigator and Staff Physician, Geriatric Research, Education, and Clinical Center (GRECC), Birmingham VA Medical Center, Birmingham, Alabama
  • Patrick O'Neil, PhDPatrick O'Neil, PhD
    Director, Weight Management Center; Professor, Department of Psychiatry and Behavioral Sciences; Professor, Department of Surgery, Medical University of South Carolina, Charleston, South Carolina
  • Donna Ryan, MDDonna Ryan, MD
    Professor Emeritus, Pennington Biomedical Research Center, Baton Rouge, Louisiana
  • Scott Kahan, MD, MPHScott Kahan, MD, MPH
    Faculty, Johns Hopkins University; Baltimore, Maryland; Director, National Center for Weight and Wellness, Washington, DC
This activity is supported by an
educational grant from
Takeda Pharmaceuticals U.S.A., Inc.
Polling Question

Over the past year, how has your comfort level changed related to providing weight-loss options for your patients with overweight or obesity?
Comfort level has increased
Comfort level has decreased
Has not changed -- always been comfortable
Has not changed -- still not comfortable

Disclosures

Steering Committee
Ken Fujioka, MD

Ken Fujioka, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eisai Co., Ltd; Enteromedics, Inc.; Gelesis; Nazura; Novo Nordisk; Zafgen; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: Abbott Laboratories; Eisai Co., Ltd; Novo Nordisk; Shire; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Eisai Co., Ltd; Enteromedics, Inc.; Orexigen Therapeutics, Inc.; Novo Nordisk; Shire

Timothy Church, MD, MPH, PhD

Timothy Church, MD, MPH, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: VIVUS Inc.
Received grants for clinical research from: VIVUS Inc.; Coca Cola; Orexigen Therapeutics, Inc.; Arena Pharmaceuticals, Inc.
Owns stocks, stocks options, or bonds from: Catapult Health; FIX: Fitness Interactive eXperience Employed by a commercial interest: ACAP Health

Timothy Garvey, MD

Timothy Garvey, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Daiichi Sankyo, Inc.; VIVUS Inc.; Eisai, Inc.; Takeda Pharmaceuticals North America, Inc.; Novo Nordisk; Janssen Pharmaceuticals, Inc.; LipoScience; Boehringer Ingelheim Pharmaceuticals, Inc.
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Merck & Co., Inc.; Weight Watchers; Sanofi; Eisai, Inc.
Owns stocks, stocks options, or bonds from: Pfizer, Inc.; Lilly; Merck & Co., Inc.; Isis Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Novartis Pharmaceuticals Corporation

Patrick O'Neil, PhD

Patrick O'Neil, PhD, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Eisai Inc.; Novo Nordisk
Received grants for clinical research from: Orexigen Therapeutics, Inc.; Weight Watchers International; Novo Nordisk
Received reimbursement for travel expenses from: VIVUS, Inc.

Donna Ryan, MD

Donna Ryan, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Novo Nordisk; Eisai, Inc.; Takeda Pharmaceuticals North America, Inc.; VIVUS Inc.; Janssen Pharmaceuticals, Inc.
Served as a speaker or a member of a speakers bureau for: Takeda Pharmaceuticals North America, Inc.
Owns stocks, stocks options, or bonds from: Scientific Intake

Scott Kahan, MD, MPH

Participation by Dr Kahan as an advisor does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.

Scott Kahan, MD, MPH, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eisai Co., Ltd; Novo Nordisk; Takeda Pharmacueticals North America, Inc.; VIVUS Inc.
Received grants for clinical research from: Eisai Co., Ltd; Novo Nordisk; Takeda Pharmacueticals North America, Inc.; VIVUS Inc.
Book Royalties (Other): Johns Hopkins University Press; Lippincott Williams & Wilkins; Wolters-Kluwer